Yes, Kaiser Permanente does cover GLP-1 medications, but whether yours will be covered depends on three things: why it was prescribed, which Kaiser plan you have, and where you live. GLP-1 drugs prescribed for type 2 diabetes are covered across Kaiser’s regions as part of the standard drug benefit. GLP-1 drugs prescribed for weight loss are covered only when your specific plan includes that benefit, and even then you’ll need to clear prior authorization and step-therapy requirements before a prescription is approved.
If the Prescription Is for Type 2 Diabetes
Kaiser generally covers GLP-1 medications for type 2 diabetes under its standard drug benefit. In the Northwest region, Ozempic (semaglutide) sits on the formulary for diabetes, though you still need to meet clinical criteria such as having tried metformin and SGLT-2 inhibitors first.1Kaiser Permanente. KP Criteria Ozempic NW Commercial Mounjaro (tirzepatide) is non-formulary in the Northwest but can be approved for diabetes when a patient has failed to reach blood sugar targets on several other medications, including semaglutide.2Kaiser Permanente. KP Mounjaro NW Criteria
What you’ll actually pay is set by your Evidence of Coverage, which varies by employer group and plan.3Kaiser Permanente. Commercial HMO Formulary Southern California
If the Prescription Is for Weight Loss
This is where Kaiser members most often run into trouble. Kaiser’s criteria documents say it plainly: drugs like Wegovy, Zepbound, and Ozempic used for weight management are covered “only for members with coverage for medications used to treat weight loss.”4Kaiser Permanente. KP Criteria Wegovy NW Commercial If your benefit package doesn’t include that coverage, you’ll pay cash.
For employer-sponsored plans, this is largely the employer’s choice. No federal law requires employer health plans to cover GLP-1 drugs for weight loss, and employers can elect to cover them for diabetes only, for both, or not at all.5MyCalChoice. Employer GLP-1 Coverage Strategies and Cost Management
California Commercial Plans Dropped Base Coverage in 2025
Effective January 1, 2025, Kaiser Permanente dropped base coverage for GLP-1 medications on its California commercial and Affordable Care Act plans when the drugs are prescribed solely for weight loss in patients with a BMI under 40.6Becker’s Hospital Review. The GLP-1 Dilemma Persists Into 2025 If your California commercial plan is affected, weight-loss GLP-1 coverage is no longer part of the standard plan unless your employer bought additional coverage or your BMI is 40 or higher.
Medi-Cal No Longer Covers GLP-1s for Weight Loss
California’s Medi-Cal program eliminated coverage for GLP-1 medications prescribed for weight loss in adults effective January 1, 2026. The legislature approved the change as part of the state budget to help close a $12 billion deficit.7California Academy of Family Physicians. Legislative Update: Health Omnibus and Key Budget Wins for Family Medicine Three drugs are now excluded from Medi-Cal coverage regardless of indication: Wegovy, Saxenda, and Zepbound. Other GLP-1 medications remain covered when prescribed for type 2 diabetes.8California Medical Association. GLP-1 Medications for Weight Loss Will No Longer Be Covered by Medi-Cal Limited exceptions exist for specific non-weight-loss uses (such as Wegovy for cardiovascular disease or Zepbound for obstructive sleep apnea) with an approved prior authorization, and patients under 21 may still qualify for weight-loss coverage through prior authorization.
What You Have to Clear Before Approval
Even when your plan does cover GLP-1s for weight loss, approval is not automatic. Kaiser treats these drugs as one piece of a broader weight-management program.9The Permanente Federation. Prescribing GLP-1s: Evidence, Limits, Expectations
Clinical Criteria
Thresholds vary somewhat by region, but the framework is consistent across Kaiser’s markets:
- A BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol.1Kaiser Permanente. KP Criteria Ozempic NW Commercial
- Active participation in a diet and exercise program.
- A documented trial and failure of at least two other weight-loss medications (such as phentermine, topiramate, or naltrexone/bupropion) over a three-month period, unless you have a documented allergy, intolerance, or contraindication.4Kaiser Permanente. KP Criteria Wegovy NW Commercial
Step Therapy
Kaiser’s Northwest region publishes drug-specific step-therapy requirements that show how this plays out. For Wegovy (injectable semaglutide for weight loss), you must first fail an adequate trial of at least two older weight-loss drugs and then fail a trial of Ozempic, the cheaper diabetes formulation of the same molecule.10Kaiser Permanente. KP Wegovy NW Criteria For Zepbound (tirzepatide for weight loss), the bar is higher: a minimum six-month trial of semaglutide (Ozempic or Wegovy) followed by a bariatric medicine chart review.11Kaiser Permanente. KP Zepbound NW Criteria The oral tablet form of Wegovy adds another step: you must fail the injectable version first, unless you have a documented needle phobia or physical disability preventing self-injection.12Kaiser Permanente. KP Criteria Wegovy Tablet NW Commercial
Keeping the Approval
Approval is not permanent. In the Northwest region, coverage is granted in 12-month increments, and to continue you must show updated weight and BMI documentation and demonstrate that you’ve achieved and maintained at least 5% weight loss since starting the drug.1Kaiser Permanente. KP Criteria Ozempic NW Commercial For members on Postal Service Health Benefits plans, monitoring is more frequent: monthly in-office exams with weigh-ins, initial approval of three to six months, and reassessment at the three-month mark.13Kaiser Permanente. Kaiser Permanente PSHB Weight Management Programs and GLP-1 Requirements
Federal Employees and Postal Workers
If you’re enrolled in Kaiser through the Federal Employees Health Benefits (FEHB) or Postal Service Health Benefits (PSHB) program, the path is clearer. Both offer GLP-1 drugs for weight loss at 50% coinsurance of the plan allowance.14Kaiser Permanente. Kaiser Permanente FEHB Weight Management Programs and GLP-1 Requirements Prior authorization still applies: a BMI of 27 or higher with a comorbidity, enrollment in lifestyle and behavioral programs, and documented failure of other weight-loss medications. Specific requirements vary by market, so check your regional plan brochure.13Kaiser Permanente. Kaiser Permanente PSHB Weight Management Programs and GLP-1 Requirements
Medicare Members
Medicare has long been prohibited by law from covering drugs used solely for weight loss. If you’re a Kaiser Medicare Advantage member, GLP-1 drugs are covered through Part D only when prescribed for an FDA-approved indication other than weight loss, such as type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea.15WellCare. Does Medicare Cover Weight Loss Drugs Kaiser’s Northwest criteria documents say explicitly that their weight-management coverage criteria “do not apply to Medicare Part D patients.”1Kaiser Permanente. KP Criteria Ozempic NW Commercial
A temporary option opened in mid-2026. The Centers for Medicare and Medicaid Services launched the “Medicare GLP-1 Bridge” program, running July 1 through December 31, 2026. The Bridge covers Wegovy and Zepbound for Medicare Part D enrollees with a BMI of 35 or higher (or 27 or higher with other clinical criteria) at a flat $50 copayment per prescription. It operates outside the standard Part D benefit, so the copayment doesn’t count toward your Part D deductible or out-of-pocket spending cap.16KFF. What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries If you’re already getting a GLP-1 covered under Part D for a non-weight-loss indication, you aren’t eligible for the Bridge.17Medicare.gov. Weight Loss Drugs Starting in 2027, access to Medicare coverage for weight-loss GLP-1s will depend on whether your specific Part D plan opts into a longer-term demonstration called the BALANCE Model.
What You’ll Pay Without Coverage
Kaiser does not publish a single price list for GLP-1 medications, and costs vary with your plan. With coverage, your cost-sharing comes from your Evidence of Coverage.3Kaiser Permanente. Commercial HMO Formulary Southern California Without weight-loss coverage, Kaiser’s internal wholesale acquisition cost for Wegovy is $1,349. Patients can access it through the manufacturer’s NovoCares program at $349 per month, with the first two doses available for $149 at least through early 2026.18Kaiser Permanente Washington. Provider E-News January 2026 Kaiser’s health encyclopedia advises members whose plans don’t cover weight-loss drugs to ask their doctor or pharmacist about patient-assistance programs or lower-cost alternatives.19Kaiser Permanente. Weight-Loss Medicines
If Your Coverage Is Denied
You can appeal. Start with an internal appeal, filed within the timeframe stated in your denial notice (60 days for Medicare Part D members). You can submit by mail, fax, or online, and your prescriber can file on your behalf.4Kaiser Permanente. KP Criteria Wegovy NW Commercial If you or your prescriber believe waiting could seriously harm your health, request an expedited appeal, which usually gets a decision within 72 hours.20Kaiser Permanente. Provider Manual – Appeals
If the internal appeal is denied, external review is available. For Medicare members, upheld denials are automatically forwarded for external review. For commercial plan members, an external review must be requested within 180 days of the internal appeal decision, and the instructions come with your appeal decision letter.20Kaiser Permanente. Provider Manual – Appeals
Because Kaiser’s rules vary by region, the Northwest region (Oregon and southwest Washington) publishes the most detailed public criteria for Ozempic, Wegovy, Zepbound, and Mounjaro, while California, Colorado, Georgia, Hawaii, Mid-Atlantic, and Washington members should consult their plan’s Evidence of Coverage or contact Member Services for the rules that apply to them.